-
Hikal Limited Announces Financial Results for Q3 FY23
Hikal Limited, a specialty chemicals manufacturer, has announced its financial results for the third quarter of fiscal year 2023 (Q3 FY23). The company reported a strong performance, with revenue and profit both increasing significantly year-over-year.
-
Hikal Limited Receives Prestigious CII-ITC Sustainability Award
Hikal Limited has been recognized for its outstanding sustainability practices by receiving the prestigious CII-ITC Sustainability Award. The award was presented to the company for its commitment to environmental protection, social responsibility, and economic sustainability.
-
Hikal Limited Expands Global Presence with New Facility in Europe
Hikal Limited has announced the opening of a new manufacturing facility in Europe. The facility will produce a range of specialty chemicals for the pharmaceutical, agrochemical, and personal care industries.
-
Hikal's Q3FY23 Revenue Rises 11% to Rs 378 Crore
Hikal Limited has announced its financial results for the quarter and nine months ended December 31, 2022. The company's revenue from operations increased by 11% to Rs 378 crore in Q3FY23, compared to Rs 340 crore in the corresponding quarter of the previous year.
-
Hikal Signs Exclusive Distribution Agreement with LGC Biosearch Technologies
Hikal Limited has entered into an exclusive distribution agreement with LGC Biosearch Technologies, a leading provider of life science products and services. Under the terms of the agreement, Hikal will distribute LGC Biosearch Technologies' products in India.
-
Hikal Appoints Mr. Ajaykumar Anjikar as CFO
Hikal Limited has announced the appointment of Mr. Ajaykumar Anjikar as its new Chief Financial Officer (CFO), effective January 16, 2023. Mr. Anjikar has over 20 years of experience in the pharmaceutical industry.
-
Hikal Awarded Prestigious CPhI Pharma Award for Best Excipient Innovation 2023
Hikal, a leading global provider of specialty chemicals and active pharmaceutical ingredients (APIs), has been recognized with the prestigious CPhI Pharma Award for Best Excipient Innovation 2023.
-
Hikal Q3FY23: Revenue up 10%, Net Profit up 25%
Hikal Limited, a leading global provider of specialty chemicals and active pharmaceutical ingredients (APIs), today announced its financial results for the quarter ended December 31, 2022.
-
Hikal Receives US FDA Approval for its API Manufacturing Facility in Goa, India
Hikal, a leading global provider of specialty chemicals and active pharmaceutical ingredients (APIs), has received approval from the US Food and Drug Administration (FDA) for its API manufacturing facility in Goa, India.
-
Hikal announces Board approval for the issue of Bonus Shares
The Board of Directors of Hikal Limited, at their meeting held on Wednesday, 15 June 2023, considered and approved the issue of Bonus Shares in the ratio of 1 (one) Equity Share for every 1 (one) Equity Share held as on the record date, subject to shareholders' approval.
-
Hikal receives USFDA approval for manufacturing site in Panoli
Hikal Limited has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing site at Panoli, Gujarat. The inspection was conducted from 6th March 2023 to 10th March 2023.
-
Hikal inaugurates its new R&D centre in Bengaluru
Hikal Limited inaugurated its new state-of-the-art R&D centre in Bengaluru on Wednesday, 15 December 2022. The new centre will house over 100 scientists and will focus on developing new and innovative products for the pharmaceutical and life sciences industries.
-
Hikal Ltd. Announces Agreement to Acquire Sterile Manufacturing Facility in Czech Republic
The acquisition will expand Hikal's global manufacturing footprint and enhance its capabilities in sterile manufacturing.
-
Hikal Ltd. Reports Strong Q3 FY23 Results
The company reported a 26% increase in revenue and a 33% increase in net profit for the quarter.
-
Hikal Ltd. Launches New API Manufacturing Facility in India
The new facility will cater to the growing demand for APIs in the pharmaceutical industry.
-
Hikal's Q1 Net Profit Falls 43% YoY to Rs 18 Crore
Hikal's financial performance for the quarter ended June 30, 2023, reflected a decline compared to the same period last year. The company's net profit decreased by 43% year-over-year, dropping from Rs 31 crore in Q1 2023 to Rs 18 crore in Q1 2024.
-
Hikal Signs Agreement to Acquire 100% Stake in Fineotex Chemical
Hikal has announced the signing of an agreement to acquire a 100% stake in Fineotex Chemical Limited, a leading manufacturer of specialty chemicals based in Gujarat, India. This strategic acquisition will further strengthen Hikal's position in the pharmaceutical and agrochemical sectors.
-
Hikal Receives USFDA Approval for Paliperidone Extended-Release Tablets
Hikal has received approval from the United States Food and Drug Administration (USFDA) for its Paliperidone Extended-Release Tablets, 1 mg, 3 mg, and 6 mg. This approval marks a significant milestone for Hikal, as it expands the company's product portfolio and strengthens its presence in the global pharmaceutical market.
